Sir Christopher Evans
Sir Chris is a renowned scientist and highly successful entrepreneur with numerous prestigious awards and medals for his work over the last 30 years. He is the founder and deputy chairman of Arix Bioscience plc, has created 11 successful academic spin-outs and founded notable companies such as Chiroscience, Celsis, BioVex, ReNeuron, Vectura and Merlin Biosciences Ltd. He was instrumental in raising approximately $450 million for Merlin Biosciences Funds and realised $2.6 billion from disposals out of these funds including the sale of BioVex Group, Inc to Amgen Inc and Piramed Limited to Roche Group.
Sir Chris has founded multiple listed companies with a collective market cap of around $3.4 billion. Appointed OBE in 1995 for services to medical bioscience, he was then knighted in 2001 for services to bioscience and enterprise.
Chief Executive Officer
Rajan is a successful international experienced CEO, and co-founder of Ellipses. He is a qualified surgeon and former adviser to multi-national corporations and governments. Through roles in both venture capital and as a CEO of life science businesses including Virgin Health Bank, Rajan has extensive experience in building growth companies in biotech, medtech and life sciences across the globe.
Rajan graduated from the University of Cambridge and is a member of the Royal College of Surgeons of England.
Professor Gordon McVie
Chairman of the Ellipses Scientific Affairs Group
Professor McVie is an international authority on the research and treatment of cancer. He is the senior Consultant to the European Institute of Oncology, Milan and Clinical Research Adviser to the FIRC Institute of Molecular Oncology (IFOM).
He is also Chairman, Proton Partners International Ltd., visiting professor at Kings College London and the University of Milan, as well as founding editor of ecancer.org, ecancerpatient.org and ecancerLatinoAmerica. Gordon is also a former joint director general of Cancer Research UK.
Chief Financial Officer
A respected life sciences CFO and qualified charted accountant, having trained with PricewaterhouseCoopers, David has extensive experience in growing drug development and biotech businesses. He is former CFO of dual-listed drug development company, Biotie and led the sale to Acorda Therapeutics for more than $350m.
David is the former CFO of VC-backed speciality pharma company, EUSA Pharma, which he helped lead from start-up, through four acquisitions and sold to Jazz Pharmaceuticals for $700m. He is also former financial controller and acting CFO of pharma company, Zeneus. David is Non-Executive Chairman of AIM-listed Alliance Pharma plc.
Chief Development Officer
As Chief Development Officer, James brings more than 30 years’ experience in the pharmaceutical and biotechnology industries covering a range of development phases and therapeutic areas, including oncology. Most recently he was Chief Development Officer at Immunocore pharmaceuticals. Prior to this, James held various senior positions at Pfizer Inc., including VP of European and Asian Development Operations, Development Team Leader within the Gastrointestinal Therapeutic Area and Development Operations Oncology Therapeutic Area Head, Europe, where he supported the successful Aromacin® EU filing and approval and has led the delivery of several global drug filings.
He holds an M.Phil from Imperial College London in Statistics and Operational research.
Jonathan has wide experience across the healthcare and pharmaceutical sectors as a former Partner and head of the Healthcare franchise at Skillcapital, a leading human capital advisory firm. Working exclusively with the private equity industry he advised on over 100 transactions and built management teams in healthcare companies internationally.
A practising solicitor, Jonathan previously worked in the private equity corporate teams at Allen & Overy and Weil, Gotshal & Manges in, London. Jonathan oversees Ellipses’ HR and Legal and many elements of our non-clinical operations.